NASDAQ: CYTX        Jefferies Global Healthcare Conference                       June 5, 2012i.     Technology & Investmen...
Safe Harbor StatementThis presentation may contain certain ‘forward-looking statements’. Allstatements, other than stateme...
i.     Technology & Investment Summaryii.    Cardiovascular Disease Pipelineiii.   Breast Reconstruction & Commercial Busi...
Cytori Investment SummaryOverview Cell therapies sourced from point-of-care device Cardiovascular disease & soft tissue ...
Cell Therapy: Fourth Tenet of Medicine                   5
Cell Therapy Platform: Innovative & Affordable                                                       Cardiovascular       ...
Cell Therapy Platform: Richest Cell Source    Number of Cells (millions) per 100 mL of tissue (1/2 cup)   45              ...
Cell Therapy Platform: Multiple TherapiesCardiovascular Disease                      Breast Reconstruction Completed two ...
i.     Technology & Investment Summaryii.    Cardiovascular Disease Pipelineiii.   Breast Reconstruction & Commercial Busi...
Cardiovascular Disease: OverviewI. Seeking European approval in 2012 in no-option chronic   myocardial ischemia patientsII...
Chronic Myocardial Ischemia (CMI)Condition: Severe form of coronary artery disease, limitsmobility, results in chest pains...
ADRCs for CMI: Targeted Delivery to Muscle                                Direct injection into                           ...
ADRCs for CMI: Clinical Trial Outcomes  20.0          Change in Max Volume of Oxygen (MV02) from Baseline to 6 & 18 months...
ADRCs for CMI: Clinical Trial OutcomesMVO2: significant change at 18 months• MVO2 correlates to improved survival         ...
Acute Myocardial Infarction (AMI/Heart Attack)Condition: Artery blockage inhibits blood flow to heartmuscle resulting in s...
ADRCs for AMI: Clinical Trial OutcomesPotential new approach for treatment of heart attacks   Safe & efficacious   Highe...
ADRCs for AMI: Clinical Trial Outcomes                        Lower abnormal ventricular beat rate                        ...
Cytori Cardiac Cell Therapy: Next StepsApproval decision for European CMI•Limited launch•Patient registry•Build market acc...
i.     Technology & Investment Summaryii.    Cardiovascular Disease Pipelineiii.   Breast Reconstruction & Commercial Busi...
Soft Tissue Repair: RESTORE Procedure Celution® approved in EU for breast reconstruction   $73 Two completed clinical tria...
Soft Tissue Repair: RESTORE ProcedurePre-Reconstruction; Post radiation   9-Mo Post-Reconstruction using   treatment & tum...
Soft Tissue Repair: Trial Outcomes                                          Takeaways:                                    ...
i.     Technology & Investment Summaryii.    Cardiovascular Disease Pipelineiii.   Breast Reconstruction & Commercial Busi...
Product Pricing                              $2,000-$12,000 for per-                              procedures cartridgeLow ...
Protected into 2030s: 46 Patents WW; 75+ Pending       Devices (Current)                   Devices             Soft Tissue...
Financial Highlights Cash and cash equivalents (3/31/12)       $34.4 Accounts receivable                         1.4 Long-...
Creating Shareholder Value in 20121.    Move product development pipeline forward      • ATHENA in U.S. for CMI & ADVANCE ...
Potential Near-Term Catalysts Receive approval (IDE clearance) to begin ATHENA CMI trialCelution® approval in additional...
Upcoming SlideShare
Loading in …5
×

Jefferies 2012 Global Healthcare Conference

1,625 views

Published on

CFO Mark Saad presents a business update on June 5, 2012

Published in: Technology, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,625
On SlideShare
0
From Embeds
0
Number of Embeds
985
Actions
Shares
0
Downloads
11
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Jefferies 2012 Global Healthcare Conference

  1. 1. NASDAQ: CYTX Jefferies Global Healthcare Conference June 5, 2012i. Technology & Investment Summaryii. Cardiovascular Disease Pipelineiii. Breast Reconstruction & Commercial Businessiv. Business & Economics 1
  2. 2. Safe Harbor StatementThis presentation may contain certain ‘forward-looking statements’. Allstatements, other than statements of historical fact, that address activities, eventsor developments that we intend, expect, project, believe or anticipate will ormay occur in the future are forward-looking statements. Such statements arebased upon certain assumptions and assessments made by our management inlight of their experience and their perception of historical trends, currentconditions, expected future developments and other factors they believe to beappropriate.The forward-looking statements included in this presentation are also subject to anumber of material risks and uncertainties. We caution investors not to placeundue reliance on the forward-looking statements contained in this presentation.We would advise reading our annual report filed with the United States Securitiesand Exchange Commission on Form 10-K for a more detailed description of theserisks. 2
  3. 3. i. Technology & Investment Summaryii. Cardiovascular Disease Pipelineiii. Breast Reconstruction & Commercial Businessiv. Business & Economics 3
  4. 4. Cytori Investment SummaryOverview Cell therapies sourced from point-of-care device Cardiovascular disease & soft tissue defects (i.e. breast recon) Device approved in Europe; starting U.S. clinical trialsValuable Pipeline Seeking chronic ischemia approval in Europe Approved to begin chronic ischemia trial in U.S EU heart attack pivotal trialCommercial Business Bridge to Higher Value Markets Build for profitable growth Seeking breast reconstruction reimbursement; path to profitability Enter/grow in emerging markets Razor-razorblade model: low COGS, high marginsPatent protection into 2030s and beyond 4
  5. 5. Cell Therapy: Fourth Tenet of Medicine 5
  6. 6. Cell Therapy Platform: Innovative & Affordable Cardiovascular Disease Fat (adipose) tissue Celution® System: Adipose-derivedfrom minor liposuction point-of-care device regenerative cells (ADRCs) 6
  7. 7. Cell Therapy Platform: Richest Cell Source Number of Cells (millions) per 100 mL of tissue (1/2 cup) 45 0.5 30 0.25 15 0 0 Multipotent Cells in Adipose Total Nucleated Cells in Adipose Multipotent Cells in BM Implication: Real-time access to a patient’s own regenerative cells is possible (No lengthy cell culture or manufacturing involved) 7
  8. 8. Cell Therapy Platform: Multiple TherapiesCardiovascular Disease Breast Reconstruction Completed two human trials  Approved in Europe Sustained functional benefit  Clinically validated for at 18 months high physician and Pivotal heart attack trial in patient satisfaction Europe underway  Seeking reimbursement US chronic heart disease trial approved to begin Discovery of New ApplicationsSoft Tissue Repair & Wounds  Demand by researchers for Approved in Europe for certain access to cells chronic wounds  Preclinical & clinical studies Independent studies investigating exploring new indications: several soft tissue applications  Acute renal failure such as burns, radiation injury,  Liver disease diabetic foot ulcers and others  Stress urinary incontinence  Ischemic stroke
  9. 9. i. Technology & Investment Summaryii. Cardiovascular Disease Pipelineiii. Breast Reconstruction & Commercial Businessiv. Business & Economics 9
  10. 10. Cardiovascular Disease: OverviewI. Seeking European approval in 2012 in no-option chronic myocardial ischemia patientsII. Initiating U.S. chronic myocardial ischemia trial 1H 2012; The ATHENA TrialIII. Enrolling pivotal (approval) heart attack trial in Europe: The ADVANCE Trial 10
  11. 11. Chronic Myocardial Ischemia (CMI)Condition: Severe form of coronary artery disease, limitsmobility, results in chest pains from ischemic tissueDisease Course: Multiple revascularization procedureswithout improvement resulting in limited therapeutic optionsSize of Market: Approx.120K to 250K diagnosed each year inU.S.; subset of approx. 5.8 MM heart failure patientsADRCs & Cell Therapy: Potential to revive living but stressedheart tissue; keep patient off transplant list; overcome limitsof existing drugs, devices and surgical options 11
  12. 12. ADRCs for CMI: Targeted Delivery to Muscle Direct injection into “hibernating” heart muscle via catheter
  13. 13. ADRCs for CMI: Clinical Trial Outcomes 20.0 Change in Max Volume of Oxygen (MV02) from Baseline to 6 & 18 months 19.0 P<0.05 P<0.05Soft Tissue RepairSoft Tissue Repair 18.0 Soft Tissue Repair 17.2 17.1 16.0 16.6 15.5 15.3 14.0 Transplant List Baseline 13 6 Mos 18 Mos ADRC’s N = 27 pts Standard of Care (6 placebo/21 treated)
  14. 14. ADRCs for CMI: Clinical Trial OutcomesMVO2: significant change at 18 months• MVO2 correlates to improved survival 28 Month Mortality Rate• MVO2 ≤ 14 = 47% 1 yr survival rateMETS: significant change at 18 months Treated 5%Cytori procedure safe and feasible through 18-months Placebo 33%Lower cardiac mortality rate:• At avg. follow-up of 28 months: - 2/6 placebo 0% 10% 20% 30% 40% - 1/21 treated 14
  15. 15. Acute Myocardial Infarction (AMI/Heart Attack)Condition: Artery blockage inhibits blood flow to heartmuscle resulting in stunned ischemic tissueDisease Course: Large attacks lead to heart failure ifischemic tissue is not revascularized;Size of Market: Approx.1 million heart attack patientsadmitted to hospital each yearADRCs & Cell Therapy: Potential to minimize heart damage;additive to existing treatments; potential to reducehealthcare costs & rehospitalizations linked to heart failure 15
  16. 16. ADRCs for AMI: Clinical Trial OutcomesPotential new approach for treatment of heart attacks Safe & efficacious Higher serious adverse event rate in Controls P < 0.05 for change from BL for ADRCs P > 0.05 for change from BL for Placebo 16
  17. 17. ADRCs for AMI: Clinical Trial Outcomes Lower abnormal ventricular beat rate  More significant Ventricular Arrhythmias in placebo  Higher frequency of recordings with Ventricular Premature Beats (VPB) in Controls  Higher #of VPBs per recording in placebo 17
  18. 18. Cytori Cardiac Cell Therapy: Next StepsApproval decision for European CMI•Limited launch•Patient registry•Build market access; top hospitals in EuropeInitiate ATHENA U.S. pilot trial for CMI•Multi-center, double-blind, 45 patients•FDA approved design in Jan 2012Accelerate enrollment in ADVANCE heart attack pivotal trial•30-35 sites to treat up to 360 patients•20+ sites selected and committed•2012 focus on getting sites online 18
  19. 19. i. Technology & Investment Summaryii. Cardiovascular Disease Pipelineiii. Breast Reconstruction & Commercial Businessiv. Business & Economics 19
  20. 20. Soft Tissue Repair: RESTORE Procedure Celution® approved in EU for breast reconstruction $73 Two completed clinical trials $126 $163 Safe: Five-plus years follow-up ClinicSoft Tissue Repair al Soft Tissuereimbursement environment Favorable Repair Partn er Limited options available to patients today ‘ADRC-Enriched $43 Graft’ Cells Fat
  21. 21. Soft Tissue Repair: RESTORE ProcedurePre-Reconstruction; Post radiation 9-Mo Post-Reconstruction using treatment & tumor resection RESTORE Procedure
  22. 22. Soft Tissue Repair: Trial Outcomes Takeaways: $73 90% • High satisfaction & safety to support 80% $126 reimbursement 70% Soft Tissue Repair Soft Tissue Repair 60% Tissue Repair • Improved breast contour at both six Soft and 12 months (blinded MRI) 50% 40% • No local cancer recurrences or serious 30% adverse events 20% 10% • Satisfactory results can be achieved in one procedure for majority of patients 0% Patient • Competitive approaches more costly: 6-Mo Satisfaction Physician lengthy hospital stays, repeat Satisfaction procedures & increase overall burden 12-Mo on healthcare systemPost-Marketing Study Design• Prospective 71 patient study
  23. 23. i. Technology & Investment Summaryii. Cardiovascular Disease Pipelineiii. Breast Reconstruction & Commercial Businessiv. Business & Economics 23
  24. 24. Product Pricing $2,000-$12,000 for per- procedures cartridgeLow six figure ASP for ASP dependent onsale & installation indications and formulation 60-80% Margin 24
  25. 25. Protected into 2030s: 46 Patents WW; 75+ Pending Devices (Current) Devices Soft Tissue Cardiovascular Therapies Pipeline Next Recon & Therapies Generation Aesthetics)US: (5) US: (1) US: (4) EUROPE: (2) US: (2)CELUTION DEVICE (‘484) CELUTION FUTURE CELUTION FOR ADRCS FOR CARDIAC (‘382) CELUTION FORCELUTION DEVICE PLUS ADDITIVES (‘420) GENERATIONS (‘075) MIXING ADRCS PLUS OPPOSED BONE (‘043)STEMSOURCE DEVICE (‘115) INDIA: (1) FAT (‘488) DEVICE FOR RESTORING BLOOD FLOW CELUTION OUTPUTCELUTION DEVICE PLUS SENSORS FOR CELUTION FUTURE CELUTION OR NEXT (‘575) PLUS PROSTHETICCLINICALLY SAFE OUTPUT (‘670) GENERATIONS (‘529) GEN DEVICES FOR AUSTRALIA: (1) FOR BONEBEDSIDE COMPREHENSIVE AUSTRALIA: (1) SOFT TISSUE DEFECTS ADRCS FOR CARDIAC (‘858) RELATEDDEVICE (‘059) CELUTION WITH (‘684) SINGAPORE: (1) DISORDERS (‘716)JAPAN: (2) CENTRIFUGE OR ADRCS PLUS FAT ADRCS FOR RESTORING BLOOD EUROPE: (2)CELUTION DEVICE (‘952) FILTER (‘937) PLUS ADDITIVES FLOW(‘590) CELUTION FORCELUTION FOR CLINICALLY SAFE OUTPUT SINGAPORE: (1) (‘795) CHINA: (1) ACUTE(‘556) CELUTION & FUTURE ADRCS PLUS FAT ADRCS FOR RESTORING BLOOD FLOW TUBULARKOREA: (3) GENERATIONS (‘672) (‘104) NECROSIS (‘834)CELUTION DEVICE (‘995) (‘683) JAPAN: (1) RUSSIA: (1) ADRCS FORSTEMSOURCE DEVICE (‘812) ISRAEL: (1) CELUTION AND NEXT CELUTION FOR RESTORING BLOOD FLOW WOUNDCELUTION DEVICE (‘139) CELUTION WITH GEN DEVICES FOR (‘924) HEALING (‘833)INDIA: (1) CENTRIFUGE OR MIXING ADRCS PLUS SOUTH AFRICA: (1) JAPAN: (1)CELUTION DEVICE (‘706) FILTER (‘800) FAT (‘041) ADRCS FOR CARDIAC (‘446) ADRCS FORAUSTRALIA: (1) MEXICO: (1) KOREA: (1) MEXICO: (1) WOUND HEALINGCELUTION DEVICE (‘135) CELUTION FUTURE ADRCS PLUS FAT CELUTION FOR RESTORING BLOOD FLOW (‘699)STEMSOURCE DEVICE (‘901) GENERATIONS (‘041) (‘775) INDIA: (1)CHINA: (1) ISREAL: (1) ADRCS FORCELUTION DEVICE (‘689) ADRCS FOR CARDIAC (‘354) WOUND HEALING (‘580)
  26. 26. Financial Highlights Cash and cash equivalents (3/31/12) $34.4 Accounts receivable 1.4 Long-term debt (GE Capital) 24.6 2011 Product sales $8.0 2011 Cost of sales 3.8 2011 Gross profit 4.1 2011 Net cash used in op. activities 35.3 2012 Revenue guidance >$9.0 2012 Research & Development Increase 2012 Sales & Marketing Reduce 2012 G&A Reduce 2012 Projected Quarterly Burn <$7 MM Total shares outstanding (4/30/12) 58.7 MM 26
  27. 27. Creating Shareholder Value in 20121. Move product development pipeline forward • ATHENA in U.S. for CMI & ADVANCE in Europe for AMI • European approval decision for no-option CMI in Europe2. Get commercial business profitable in 12-18 months • 20+% annual revenue growth until inflection point • Focus on breast reconstruction reimbursement in UK • Build market access for no-option CMI in Europe • Expand regulatory approvals and indications3. Execute on Corporate Milestones • Development and commercialization partnerships (i.e. Astellas) • Reduce total operating expenses & burn through G&A and S&M reductions offset with increase in R&D
  28. 28. Potential Near-Term Catalysts Receive approval (IDE clearance) to begin ATHENA CMI trialCelution® approval in additional countries (Russia May ’12, more to come)Initiate ATHENA trial in U.S.CE Mark for chronic myocardial ischemiaBreast reconstruction technology evaluation in UKStrategic Partner(s)

×